458 reports of this reaction
1.9% of all VALGANCICLOVIR HYDROCHLORIDE POWDER, reports
#13 most reported adverse reaction
TRANSPLANT REJECTION is the #13 most commonly reported adverse reaction for VALGANCICLOVIR HYDROCHLORIDE POWDER,, manufactured by Ajanta Pharma USA Inc.. There are 458 FDA adverse event reports linking VALGANCICLOVIR HYDROCHLORIDE POWDER, to TRANSPLANT REJECTION. This represents approximately 1.9% of all 24,571 adverse event reports for this drug.
Patients taking VALGANCICLOVIR HYDROCHLORIDE POWDER, who experience transplant rejection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TRANSPLANT REJECTION is a less commonly reported adverse event for VALGANCICLOVIR HYDROCHLORIDE POWDER,, but still significant enough to appear in the safety profile.
In addition to transplant rejection, the following adverse reactions have been reported for VALGANCICLOVIR HYDROCHLORIDE POWDER,:
The following drugs have also been linked to transplant rejection in FDA adverse event reports:
TRANSPLANT REJECTION has been reported as an adverse event in 458 FDA reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,. This does not prove causation, but indicates an association observed in post-market surveillance data.
TRANSPLANT REJECTION accounts for approximately 1.9% of all adverse event reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,, making it a notable side effect.
If you experience transplant rejection while taking VALGANCICLOVIR HYDROCHLORIDE POWDER,, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.